echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > AAD 2020: Lebrikizumab treatment for aspecific dermatitis, significant improvement in the quality of life of patients

    AAD 2020: Lebrikizumab treatment for aspecific dermatitis, significant improvement in the quality of life of patients

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Lilly and its wholly-owned subsidiary Dermira announced that they will present the latest data on the trial of lebrikizumab's phase IIb clinical trial for moderate to severe aditial dermatitis at the 2020 Virtual Meeting of the American Society of Dermatology (AAD)This study shows that Lebrikizumab can provide rapid and clinically meaningful improvements in patients' itching, sleep and quality of lifeProfessor Clara Kest, Director of the Department of Dermatological Dermatism at The Icahn School of Medicine at Mount Sinai, said: "Understanding the potential of lebrikizumab to improve skin symptoms and other common symptoms in patients with teriotmatitis, such as itching and lack of sleep, is critical to understanding the true potential of lebrikizumabThese results suggest that lebrikizumab can significantly improve the symptoms of the most troubled patients."Aditaphilive dermatitis is a chronic, itchy, inflammatory skin disease that most often affects children, but also affects many adultsClinical features of adhesion dermatitis include dry skin, erythema, oozing and knotting, as well as moss-like changes
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.